Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 28;7:328. doi: 10.1186/s40425-019-0794-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Checkpoint inhibition results in dynamic changes in immune infiltrate in CT-26. (a) Schematic of treatment and sample collection in CT-26 model. (b) Representative sunburst plot showing T-cell population changes after α-mPD-L1+ α-mCTLA-4 treatment in CT-26 tumors. (c) Representative sunburst plot showing changes in myeloid populations after α-mPD-L1+ α-CTLA-4 treatment in CT-26 tumors. (d) Flow cytometry data for individual T-cell populations from isotype control treated (n=20) or α-mPD-L1+ α-CTLA-4 treated (n=17) tumors. (e) Flow cytometry data for individual macrophage populations from isotype control treated (n=20) or α-mPD-L1+ α-CTLA-4 treated (n=17) tumors. (f) Gene expression data generated from a panel of 96 genes was used to calculate a GSVA score [4, 5] indicating enrichment for specific immune cell types after treatment with isotype control (n=10) or α-mPD-L1+ α-CTLA-4 (n=9) in CT-26 tumors. (g) Schematic of Treatment and sample collection in MC38 model. (h) Representative sunburst plots showing T-cell population changes after α-mPD-L1+ α-mCTLA-4 treatment in MC38 tumors. (i) Representative sunburst plots showing changes in myeloid populations after α-mPD-L1+ α-mCTLA-4 treatment in MC38 tumors. (j) Flow cytometry data for individual T-cell populations from isotype control treated (n=20) or α-mPD-L1+ α-CTLA-4 treated (n=18) tumors. (k) Flow cytometry data for individual macrophage populations from isotype control treated (n=20) or α-mPD-L1+ α-CTLA-4 treated (n=18) tumors. (l) Gene expression data generated from a panel of 96 genes was used to calculate a GSVA score [4, 5] indicating enrichment for specific immune cell types after isotype control (n=6) or α-mPD-L1+ α-CTLA-4 (n=9) treatment in MC38 tumors. Data for sunburst plots available in Additional files 7, 8: Tables S7 and S8